1. At a Glance – The Injection That Hit the Bull’s Eye
Current price: ₹1,500
Stock P/E: 27.1
ROCE: 18.4%
ROE: 16.3%
Debt to Equity: 0.38
3-Month Return: 50.1%
1-Year Return: 89.4%
Sales (TTM): ₹462 crore
PAT (TTM): ₹57 crore
This is a pharma company that went from struggling margins a few years ago to a 23% OPM machine. And suddenly, after years of sleepy movement, the stock wakes up and runs like it just discovered caffeine.
Question is — is this sustainable biology or just quarterly chemistry?
Let’s investigate.
2. Introduction – From SME to Serious Contender
Incorporated in 1983, Kwality Pharma didn’t exactly start life as a glamorous biotech darling. It migrated from the BSE SME platform to the main board in June 2022 — which is like moving from gully cricket to Ranji Trophy.
Today, it’s ANVISA and EU GMP certified. That’s not small talk in pharma. That means global doors are open — Brazil, Europe, Latin America.
It has 3,000+ formulations across 25+ therapeutic areas. Generics, cephalosporins, beta-lactams, oncology, biologics. Basically, if there’s a disease, they probably have something injectable for it.
Export contribution in FY23: 48%
Domestic: 52%
They export to 60+ countries, including Middle East, French West Africa, Latin America, and now pushing into Brazil and EU.
And they’re not just
